China National Biotech Group Co Ltd announced on Tuesday the phase-1 and phase-2 clinical trials of its inactivated vaccine had demonstrated good in safety and effectiveness on vaccinated volunteers. No subjects showed adverse reactions, the said.

国药中国生物6月16日宣布，其新冠病毒灭活疫苗Ⅰ/Ⅱ期临床试验在接种的志愿者身上表现出良好的安全性和有效性，受试者无一例严重不良反应。

The company said a total of 1,120 volunteers were vaccinated during the phase-1 and phase-2 clinical trials, all of whom produced high-titer antibodies.

国药中国生物介绍，Ⅰ/Ⅱ期临床研究受试者共1120人，疫苗组接种者均产生高滴度抗体。

In the 18-to-59-year-old age group, those who got two doses of vaccine based on the 0-and-28-day procedure demonstrated 100 antibody conversion rate, while those who got two doses based on the 0-and-14-day procedure and 0-and-21-day procedure showed a 97.6 percent antibody positive conversion rate.

在18—59岁健康受试者中，按照0/28天程序接种两剂后，受试者中和抗体阳转率达****。按照0/14天和0/21天程序接种后的受试者中和抗体阳转率为97.6%。

The results were the world's first clinical data on safety and effectiveness collected after two doses of vaccination, offering and measurable for epidemic prevention and control and use.

这也是全球**接种两剂疫苗后收集到的临床安全性及有效性数据，为疫情防控和紧急使用提供了科学、可评价的数据。

It has received cooperation overtures from companies and institutions overseas. once the inactivated vaccine completes the three trials, it is to hit the market by the end of this year or the beginning of next year.

该公司已经收到了海外几家公司和机构的合作意向。灭活疫苗完成三期试验之后，有望于今年年底或明年初面市。

To date, four inactivated vaccines and one adenovirus vaccine have been approved for clinical trials. While scientists in China and abroad have kept up with mutual developments, China leads the world in the development of certain types of vaccines.

目前，已有4种灭活疫苗和1种腺病毒载体疫苗获批开展临床试验，总体研发进度与国外持平，部分技术路线进展处于国际**。